Vaccines in practice

Reference list

Glennie L, Coleman R. The future of meningococcal B vaccines. Vaccines in practice 2009. 2.1: 1–3.

1. Data compiled from:

•Health Protection Scotland Immunisation and Respiratory Quarterly Report 1 Oct to 31 Dec 2007; Vol. 42 No.2008/05. http://www.documents.hps.scot.nhs.uk/ewr/pdf2008/0805.pdf (last accessed 07/07/09)

• Health Protection Agency Health Protection Report Vol 2 No. 08. Feb 2008. http://www.hpa.org.uk/hpr/archives/2008/hpr0808.pdf (last accessed 07/07/09)

• CDSCNI Monthly Report Vol 17, 2008. http://www.cdscni.org.uk/publications/MonthlyReports/Volume_17_2008/MonthlyReportVol17No2.pdf (last accessed 07/07/09)

2. National Institute for Health and Clinical Excellence. Feverish Illness: assessment and initial management in children younger than 5 years. London: NICE, 2007. http://www.nice.org.uk/guidance/CG47 (last accessed 07/07/09)

3. Scottish Intercollegiate Guidelines Network. Management of invasive meningococcal disease in children and young people. Edinburgh: SIGN, 2008.

4. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007; 369: 2196–2210.

5. WHO weekly epidemiological record. 2001; 76: 281–288 http://www.who.int/docstore/wer/pdf/2001/wer7637.pdf (last accessed 07/07/09)

6. Kwara A, Adegbola RA, Corrah PT et al. Meningitis caused by a serogroup W135 clone of the ET-37 complex of Neisseria meningitidis in West Africa. Trop Med Int Health 1998; 3: 742–746

7. Harrison LH. A multivalent conjugate vaccine for prevention of meningococcal disease in infants. JAMA 2008; 299: 217–219.

8. Roberts L. Infectious disease. An ill wind, bringing meningitis. Science 2008; 27: 1710–1715.

9. Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983; 2: 355–357.

10. Jennings HJ, Roy R, Gamian A. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J Immunol 1986; 137: 1708–1713.

11. Bruge J, Bouveret-Le Cam N, Danve B, Rougon G, Schulz D. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine 2004; 22: 1087–1096.

12. Boslego J, Garcia J, Cruz C et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 1995; 13: 821–829.

13. Sierra GV, Campa HC, Varcacel NM et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991; 14: 195–207.

14. Bjune G, Høiby EA, Grønnesby JK et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991; 338: 1093–1096.

15. Galloway Y, Stehr-Green P, McNicholas A, O'Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol 2009; 38: 413–418.

16. Neisseria meningitidis PorA variable regions database. University of Oxford. (Cited 2008 December 15) http://neisseria.org/nm/typing/pora (last accessed 6/05/09)

17. Tappero JW, Lagos R, Ballesteros AM et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999; 281: 1520–1527.

18. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection—serum bactericidal antibody activity. Vaccine 2005. 23: 2222–2227.

19. Loring BJ, Turner N, Petousis-Harris H. MeNZBTM vaccine and epidemic control: When do you stop vaccinating? Vaccine 2008; 26: 5899–5904.

20. de Kleijn ED, de Groot R, Labadie J et al. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine 2000; 18: 1456–1466.

21. Jódar L, Feavers IM, Salisbur D, Granoff DM. Development of vaccines against meningococcal disease. Lancet 2002; 359: 1499–1508.

22. Finney M, Vaughan T, Taylor S et al. Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Hum Vaccin 2008; 4: 23–30.

23. Tettelin H, Saunders NJ, Heidelberg J et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 2000; 287: 1809–1815.

24. Giuliani MM, Adu-Bobie J, Comanducci M et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 2006; 103: 10834–10839.

25. Snape MD, Dawson T, Morant A et al. Immunogenicty and reactogenicity of a novel serogroup B Neisseria meningitidis vaccine administered from 6 months of age. International Pathogenic Neisseria Conference, 2008. http://neisseria.org/ipnc/2008/Abstracts_oral_presentations_IPNC_2008.pdf

26. Oster P. Advances in Vaccine Development for Meningococcal Serogroup B Disease. Presentation. Meningitis Research Foundation Conference, 2007.

27. Fletcher LD, Bernfield L, Barniak V et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Vaccine 2004; 72: 2088–2100.

28. Beernink PT, Granoff DM. Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines. Infect Immun 2008; 6: 2568–2575.

29. Murphy E, Andrew L, Lee KL et al. Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup B Neisseria meningitidis. J Infect Dis 2009; 200: 379–389.

30. Jansen KU, McNeil LK, Dragalin V et al. Bivalent recombinant LP2086 vaccine to provide broad protection against Neisseria meningitidis B disease: Immunological correlates of protection and how to assess coverage against invasive MnB strains International Pathogenic Neisseria Conference, 2008.

http://neisseria.org/ipnc/2008/Abstracts_oral_presentations_IPNC_2008.pdf

31. Richmond P, Marshall H, Nissen MD et al. A randomized, observer-blinded, active control, phase 1 trial of meningococcal serogroup B rLP2086 vaccine in healthy children and adolescents aged 8 to 14 years. International Pathogenic Neisseria Conference Rotterdam 2008, P212. http://neisseria.org/ipnc/2008/Abstracts_poster_presentations_IPNC_2008.pdf

32. Keiser PB, Moran EE, Schmiel DH et al. A phase 1 study of the safety and immunogenicity of an intramuscular group B meningococcal NOMV vaccine made from an lpxL2 and synX deleted strain. International Pathogenic Neisseria Conference Rotterdam 2008, P215. http://neisseria.org/ipnc/2008/Abstracts_poster_presentations_IPNC_2008.pdf

33. Weynants VE, Feron CM, Goraj KK et al. Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis. Infect Immun 2007; 75: 5434–5442.

34. Borrow R, Carlone GM, Rosenstein N et al. Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16–17 March 2005. Vaccine 2006; 24: 5093–5107.

35. http://www.meningitis.org/current-projects (last accessed 07/07/09).

36. Heyderman RS, Davenport V, Williams NA. Mucosal immunity and optimizing protection with meningococcal serogroup B vaccines. Trends Microbiol 2006; 14: 120–124.

Published by Hayward Medical Communications

www.hayward.co.uk